The Latest Breaking News from LLY

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Investors could snag these two stocks as BofA flags the companies as well-positioned winners in an uncertain quarter.

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.